Projects

The overall goal of our translational research program is to develop novel therapeutics and pharmacologically-driven strategies for improving the treatment of cancer patients. There are two major project areas:

DRUG DELIVERY SYSTEMS BASED ON HIGH-AFFINITY NATURALLY-OCCURRING HUMAN PROTEINS.

These projects exploit the high affinity and selectivity for protein hormones and receptor ligands to carry cancer therapeutics to solid tumors and leukemias that over-express the LGR4, LGR5, and LGR6 receptors.

DEVELOPOMENT OF THE NOVEL FUSION PROTEIN THERAPEUTIC CYMIRAFEN FOR THE TREATMENT OF MULTIPLE TYPES OF CANCER.

Cymirafen is a novel type of protein therapeutic that uses the receptor binding domains of RSPO1 to deliver cancer therapeutics to multiple types of cancer. Cymirafen is the first drug derived from the Cyspondin drug delivery platform. In vitro and in vivo IND-enabling studies are underway that will advance this drug into pre-clinical development.